NCT01623713

Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia

A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 260 (actual)
• Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether iloperidone is effective in the treatment of Schizophrenia.

Conditions

• Schizophrenia
• Iloperidone
• Efficacy

Interventions

Type	Name	Description
DRUG	iloperidone	Iloperidone is being development as a treatment of schizophrenia. This trial will verify the safety and efficacy of iloperidone in patients with schizophrenia.
DRUG	Risperidone	Risperidone is used for the treatment of schizophrenia.Risperidone is unique among most other atypicals in that it has high affinity for the D2 receptor whereas most other atypicals have 'loose binding' of the D2 receptor. It has actions at several 5-HT (serotonin) receptor subtypes.

Timeline

• Start date: 2012-06-01
• Primary completion: 2013-10-01
• Completion: 2013-11-01
• First posted: 2012-06-20
• Last updated: 2013-11-19

Locations

1 site across 1 country: China